Home › Catalysts
Quarter catalyst calendar
What lands in 4Q 2026, a look ahead to 1Q 2027, and the rest of the next twelve months below that. Dates are the company's own guidance as reported in Biotech Distilled coverage — most are windows rather than fixed days, and each row says which it is. Click any catalyst to read the latest post on it.
Updated November 7, 2026 · 316 events
No catalysts match these filters.
This quarter · dated
55the company named a day or a month; ~ marks an approximate date
- Oct–Nov 2026 IONS Watch Ionis corporate update material
- Nov 2026 PEPG Spec buy PGN-EDODM1 topline thesis-defining
- Nov 2026 INAB Watch INB-200/INB-400 Ph2 interim major
- Nov 2026 RVMD Buy RASONQUE daraxonrasib corporate update material
- Nov 2026 CLNN Hold CLNN filing notable
- Nov 2026 CMPS Buy COMP360 TRD NDA filing notable
- Nov 2026 COYA Avoid COYA 302 ALS corporate update notable
- ~Nov 2026 HRMY Watch WAKIX / MSN License Agreement notable
- Nov 2026 NRXP Spec buy Corporate financials filing notable
- Nov 6–9, 2026 MLYS Watch Lorundrostat AHA readout material
- Nov 7, 2026 MDNAF Hold MDNA11 SITC Ph1 topline major
- Nov 8, 2026 VIR Buy ECLIPSE 1 Ph3 topline thesis-defining
- Nov 8–11, 2026 NKTX Watch NKX019 Ntrust-2 readout material
- Nov 8–10, 2026 CABA Buy RESET program aggregate safety / notable
- Nov 9, 2026 FATE Watch FT819 Ph1 readout major
- Nov 9, 2026 ALLO Hold ALLO-329 Ph1 interim material
- Nov 9, 2026 JANX Buy JANX011 Ph1 interim material
- Nov 12–14, 2026 KTTA Buy PAS-004 Ph1 topline thesis-defining
- Nov 14, 2026 SMMT Buy ivonescimab NSCLC PDUFA date thesis-defining
- Nov 14, 2026 RCUS Buy Summit ivonescimab PDUFA date material
- Nov 15, 2026 AMLX Spec buy avexitide LUCIDITY Ph3 readout material
- Nov 16, 2026 IDYA Watch IDE892/MTAP/CDKN2A/KRAS readout notable
- Nov 16, 2026 IMNM Spec buy BMS resale registration filing notable
- Nov 20, 2026 PMVP Spec buy Rezatapopt topline thesis-defining
- Nov 22, 2026 CAPR Spec buy Deramiocel PDUFA date thesis-defining
- Nov 28, 2026 PYPD Spec buy D-PLEX₁₀₀ PDUFA date thesis-defining
- Nov 30, 2026 COGT Buy Bezuclastinib + sunitinib GIST PDUFA thesis-defining
- Nov 30, 2026 MLYS Watch Lorundrostat reimbursement notable
- Dec 2026 ADCT Spec buy ZYNLONTA + glofitamab topline thesis-defining
- Dec 2026 KOD Hold KSI-101 Ph3 topline thesis-defining
- Dec 2026 MLTX Watch Sonelokimab HS PDUFA date thesis-defining
- Dec 2026 ADCT Spec buy ZYNLONTA monotherapy MZL readout material
- Dec 2026 CGEM Buy CLN-978 readout material
- Dec 2026 PRLD Watch Incyte JAK2V617F next-gen readout material
- Dec 2026 ZNTL Spec buy Azenosertib China decision material
- Dec 2026 CADL Watch CADL corporate filing notable
- Dec 2026 ELVN Watch ELVN-001 relcobatinib interim notable
- Dec 2026 NRSN Avoid PrimeC filing notable
- Dec 1, 2026 TLX Watch ITM acquisition strategic review notable
- Dec 4, 2026 CMMB Avoid Chemomab/Scipher merger vote strategic review notable
- Dec 8–11, 2026 OLMA Watch Olema industry event readout notable
- Dec 9, 2026 PRQR Spec buy AX-0810 Ph1 readout major
- Dec 12, 2026 ANAB Spec buy Imsidolimab FDA approval material
- Dec 12, 2026 VNDA Watch Imsidolimab FDA approval material
- Dec 14, 2026 RLAY Watch Zovegalisib ReInspire readout material
- Dec 14, 2026 IMNM Spec buy IM-1021 ADC interim notable
- Dec 14, 2026 SLS Watch SLS009 Tambiciclib readout notable
- Dec 18, 2026 OLMA Watch Giredestrant PDUFA date major
- Dec 18, 2026 BDTX Watch Black Diamond corporate China decision material
- Dec 18, 2026 CTNM Watch WuXi AppTec / BIOSECURE FDA material
- Dec 22, 2026 MLYS Watch Lorundrostat FDA decision thesis-defining
- Dec 22, 2026 OCGN Avoid Proposal 1 vote FDA decision material
- Dec 23, 2026 LEGN Spec buy anito-cel Arcellx PDUFA date thesis-defining
- ~Dec 29, 2026 TLSA Avoid Intranasal foralumab MSA FDA decision material
- Dec 30, 2026 COGT Buy Bezuclastinib NonAdvSM PDUFA date thesis-defining
This quarter · guided to 4Q 2026
67
committed to the quarter, no finer date given
- 4Q 2026 ANNX Watch Vonaprument Ph3 topline thesis-defining
- 4Q 2026 BIOA Hold BGE-102 topline thesis-defining
- 4Q 2026 HELP Spec buy HLP003 Ph3 topline thesis-defining
- 4Q 2026 ZBIO Spec buy Obexelimab SLE Ph2 topline thesis-defining
- 4Q 2026 ZURA Watch Tibulizumab TibuSHIELD topline thesis-defining
- 4Q 2026 ACHV Watch Cytisinicline smoking cessation NDA filing major
- 4Q 2026 ACRS Hold bosakitug Ph2 topline major
- 4Q 2026 ACRS Hold bosakitug topline major
- 4Q 2026 BDTX Watch Silevertinib FDA feedback major
- 4Q 2026 CADL Watch aglatimagene besadenovec BLA filing major
- 4Q 2026 GPCR Hold aleniglipron Ph2 topline major
- 4Q 2026 KYTX Buy Miv-cel BLA filing major
- 4Q 2026 SPRB Buy TA-ERT tralesinidase alfa BLA filing major
- 4Q 2026 VYGR Watch VY7523 interim major
- 4Q 2026 AARD Avoid ARD-101 FDA feedback material
- 4Q 2026/1Q 2027 ACHV Watch Cytisinicline smoking cessation corporate update material
- 4Q 2026 ANNX Watch Tanruprubart BLA filing material
- 4Q 2026 BDTX Watch Silevertinib Ph2 readout material
- 4Q 2026 BIOA Hold QUELL-CV topline material
- 4Q 2026 CMPX Avoid Tovecimig BLA filing material
- 4Q 2026 ENTA Spec buy EDP-978 Ph1 topline material
- 4Q 2026 IPSC Spec buy CNTY-813 IND filing material
- 4Q 2026 KYTX Buy SPS BLA filing material
- 4Q 2026 NVCT Spec buy NXP200 U.S. IND filing material
- 4Q 2026 RCUS Buy quemliclustat Ph3 interim material
- 4Q 2026 SLS Watch SLS009 AML Ph2 topline material
- 4Q 2026 SMMT Buy ivonescimab NSCLC interim material
- 4Q 2026 SNDX Buy Revuforj 4Q26 revumenib readout material
- 4Q 2026 SNDX Buy BEAT AML, SAVE, 708 intensive-chemo material
- 4Q 2026 VRDN Buy VRDN-008 Ph1 readout material
- 4Q 2026 WVE Hold AATD program Ph1 readout material
- 4Q 2026 ABSI Buy ABS-201 Endometriosis Ph2 start notable
- 4Q 2026 ALDX Avoid FDRR appeal corporate update notable
- 4Q 2026 ARVN Watch ARV-806 KRAS readout notable
- 4Q 2026 BDTX Watch BH-30643 BlossomHill FDA feedback notable
- 4Q 2026 CADL Watch linoserpaturev interim notable
- 4Q 2026 CGEM Buy CLN-049 Ph2 readout notable
- 4Q 2026 CGON Buy cretostimogene BLA HR filing notable
- 4Q 2026 CMPX Avoid CTX-8371 Ph1 readout notable
- 4Q 2026 CMPX Avoid CTX-10726 Ph1 readout notable
- 4Q 2026 CNTB Watch Rademikibart FDA feedback notable
- 4Q 2026 COGT Buy CGT1815 pan-KRAS Inhibitor IND filing notable
- 4Q 2026 COGT Buy CGT1145 IND filing notable
- 4Q 2026 COYA Avoid Clene CNM-Au8 NDA filing notable
- 4Q 2026 CUE Buy CUE-221 Ph2b start notable
- 4Q 2026 ENTA Spec buy RESOLVE Ph2b start notable
- 4Q 2026 EWTX Watch EDG-7500 Ph3 start notable
- 4Q 2026 FDMT Watch 4D-710 AEROW Ph1 readout notable
- 4Q 2026 GLUE Buy MRT-8102 GFORCE-3 Ph2 start notable
- 4Q 2026 GLUE Buy MRT-9347 IND filing notable
- 4Q 2026 INBX Spec buy Ozekibart FDA feedback notable
- 4Q 2026 KZIA Watch Paxalisib HR trial start notable
- 4Q 2026 MBRX Avoid Annamycin filing notable
- 4Q 2026 PRLD Watch PRT13722 trial start notable
- 4Q 2026 RCUS Buy ARC-20 cohorts cas+axitinib trial start notable
- 4Q 2026 RCUS Buy PEAK-20 trial start notable
- 4Q 2026 REPL Buy RP2 readout notable
- 4Q 2026 RNTX Watch LTI-03 Ph2 interim notable
- 4Q 2026 SABS Spec buy SAB-142 enrollment done notable
- 4Q 2026 SCYX Watch SCY-770 Ph2 start notable
- 4Q 2026 VERA Buy Atacicept PIONEER Ph2 readout notable
- 4Q 2026 VYGR Watch VY1706 trial start notable
- 4Q 2026 WVE Hold WVE-008 filing notable
- 4Q 2026 ZBIO Spec buy ZB021 Ph1 readout notable
- late 4Q 2026 SLDB Spec buy SGT-003 FDA feedback thesis-defining
- late 4Q 2026 ABVX Watch Obefazimod NDA filing material
- late 4Q 2026 GUTS Hold Revita filing notable
Could land this quarter — no finer guidance
47
a six- to twelve-month window that overlaps this quarter by construction; shown in full on each company's page
- 2026 BCTX Avoid Bria-IMT + CPI Ph3 interim major
- 2026 NKTX Watch NKX019 Ntrust-1 readout major
- 2026 SANA Hold SC451 T1D IND filing material
- 2026 IMTX Hold IMA402 Ph1 interim notable
- 2026 KYTX Buy Miv-cel Ph1 readout notable
- 2026 STRO Buy STRO-006 IND filing notable
- 2H 2026 CHRS Hold Casdozokitug Ph2 topline thesis-defining
- 2H 2026 GNLX Watch Olvi-Vec OnPrime Ph3 topline thesis-defining
- 2H 2026 INKT Watch agenT-797 topline thesis-defining
- 2H 2026 RXRX Watch REC-4881 FDA feedback thesis-defining
- 2H 2026 ABSI Buy ABS-201 AGA interim major
- 2H 2026 BBOT Spec buy BBO-10203 readout major
- 2H 2026 BBOT Spec buy BBOT pipeline BBO-11818 Ph1 readout major
- 2H 2026 INAB Watch INB-400 FDA feedback major
- 2H 2026 BBOT Spec buy BBO-11818 Ph1 interim material
- 2H 2026 ERAS Watch ERAS-4001 Ph1 interim material
- 2H 2026 LRMR Hold nomlabofusp filing material
- 2H 2026 ANNX Watch ANX1502 POC readout notable
- 2H 2026 ARVN Watch ARV-393 Ph1 interim notable
- 2H 2026 ENTA Spec buy EPS-3903 IND filing notable
- 2H 2026 INSM Watch ARIKAYCE Japan filing notable
- 2H 2026 PALI Watch PALI-2108 CD IND filing notable
- 2H 2026 QNRX Hold QRX003 Ph2 readout notable
- 2H 2026 QNRX Hold QRX003 PSS Ph2 start notable
- 2H 2026 STRO Buy STRO-227 IND filing notable
- 2H 2026 VIR Buy VIR-5818 Ph1 readout notable
- 2H 2026 ZBIO Spec buy Obexelimab MAA filing notable
- late 2026 or early 2027 DRTS Spec buy Alpha DaRT SCC pivotal topline thesis-defining
- by the end of 2026 or early 2027 IDYA Watch IDE849 Ph1 topline thesis-defining
- By end of 2026 IMUX Watch vidofludimus calcium Ph3 topline thesis-defining
- by year-end 2026 KYMR Buy KT-621 BROADEN2 Ph2b topline thesis-defining
- year-end 2026 or early 2027 TGTX Watch Subcutaneous ublituximab Ph3 topline thesis-defining
- year-end 2026 APVO Avoid Mipletamig Ph2 readout major
- Year-End 2026 BEAM Spec buy risto-cel BLA filing major
- late 2026 CLDX Buy Barzolvolimab Atopic Dermatitis Ph2 topline major
- By year-end 2026: PIKture-01 "mature data" OKUR Watch OKI-219 readout major
- Year-end 2026 NAMS Watch RUBENS obicetrapib Ph3 topline material
- By YE2026 RLAY Watch Zovegalisib 1L combo FDA feedback material
- ~YE 2026 XNCR Buy XmAb942 UC interim material
- by the end of 2026 ARDX Avoid Tenapanor ACCEL enrollment done notable
- near the end of 2026 or early 2027 ETON Buy Amglidia NDA filing notable
- late 2026 IMNM Spec buy IM-1335 IND filing notable
- Late 2026 INAB Watch INB-100 enrollment done notable
- By year-end 2026 IRON Buy Bitopertin filing notable
- before the end of this year QTTB Watch Bempikibart FDA feedback notable
- year-end 2026 RLMD Watch NDV-01 IND filing notable
- YE 2026 SNDX Buy SNDX-4321 EGFR IND filing notable
Next quarter · 1Q 2027 preview
80
quarter-precision or finer
- 1Q 2027 BMEA Avoid Icovamenib topline thesis-defining
- 1Q 2027 BMEA Avoid Icovamenib COVALENT-211 topline thesis-defining
- 1Q 2027 CBIO Buy CR-001 Ph1 topline thesis-defining
- 1Q 2027 IRD Hold OPGx-BEST1 4.5e9 vg Ph3 topline thesis-defining
- 1Q 2027 MBRX Avoid Annamycin topline thesis-defining
- 1Q 2027 OCGN Avoid OCU400 Ph3 topline thesis-defining
- 1Q 2027 OLMA Watch Palazestrant topline thesis-defining
- 1Q 2027 PMN Watch PMN310 topline thesis-defining
- 1Q 2027 RNAC Buy Descartes-08 AURORA topline thesis-defining
- 1Q 2027 SEPN Watch SEP-479 Ph1 topline thesis-defining
- Jan 2027 TECX Watch TX45 topline thesis-defining
- 1Q 2027 TTRX Spec buy GX-03 eczema Ph2 topline thesis-defining
- 1Q 2027 XENE Hold Azetukalner MDD Ph3 topline thesis-defining
- ~Jan–Mar 2027 ABVX Watch Obefazimod FDA decision major
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph1 interim major
- 1Q 2027 AXSM Avoid solriamfetol ENGAGE Ph3 topline major
- 1Q 2027 CGEN Watch COM701 interim major
- 1Q 2027 GUTS Hold Revita pivotal topline major
- 1Q 2027 NAMS Watch PREVAIL obicetrapib readout major
- 1Q 2027 NKTR Watch Rezpegaldesleukin AD readout major
- 1Q 2027 ORKA Buy ORKA-002 Ph2 topline major
- Jan 2027 PRQR Spec buy AX-0811 Ph1 interim major
- 1Q 2027 SRPT Spec buy ELEVIDYS readout major
- 1Q 2027 SRPT Spec buy ELEVIDYS ENDEAVOR readout major
- 1Q 2027 ACET Watch Prula-cel interim material
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph2 readout material
- 1Q 2027 CBIO Buy CR-003 / SKB105 Ph1 readout material
- Jan 2027 CTMX Spec buy Varseta-M (CX-2051) mCRC monotherapy Phase material
- 1Q 2027 DYN Buy z-basivarsen pivotal topline material
- 1Q 2027 EXEL Hold STELLAR-304 topline material
- 1Q 2027 FDMT Watch Ixo-vec ARTEMIS Ph3 topline material
- 1Q 2027 GANX Avoid GT-02287 Ph2 start material
- 1Q 2027 LENZ Hold VIZZ China decision material
- 1Q 2027 MLTX Watch Sonelokimab PsA topline material
- 1Q 2027 MLTX Watch Sonelokimab HS topline material
- 1Q 2027 NAMS Watch PREVAIL obicetrapib interim material
- 1Q 2027 PMVP Spec buy Rezatapopt NDA filing material
- 1Q 2027 TECX Watch TX45 readout material
- Jan 2027 TNGX Buy Vopimetostat monotherapy lung cancer Ph1 material
- Jan 2027 TNGX Buy TNG456 Ph1 interim material
- 1Q 2027 VIR Buy ECLIPSE 2 and 3 topline material
- Jan 2027 ETON Buy ASN-001 NDA filing notable
- 1Q 2027 INBX Spec buy Ozekibart interim notable
- 1Q 2027 KZIA Watch Paxalisib colorectal Ph2 start notable
- early 1Q 2027 PTGX Hold PN-881 Ph2b start notable
- 1Q 2027 PTGX Hold PN-8047 Ph1 start notable
- 1Q 2027 PTGX Hold Silence Therapeutics acquisition by Merck notable
- 1Q 2027 SEPN Watch SEP-204 Ph1 start notable
- 1Q 2027 SLDB Spec buy SGT-212 Ph1 readout notable
- 1Q 2027 SNDX Buy Niktimvo cGVHD axatilimab Ph2 readout notable
- 1Q 2027 STOK Watch Zorevunersen NDA filing notable
- 1Q 2027 TLSA Avoid Intranasal foralumab Alzheimer's Ph2 readout notable
- Jan 10, 2027 ETON Buy VALTOCO / LIBERVANT 12+ FDA material
- Jan 21, 2027 DYN Buy z-rostudirsen FDA decision major
- Jan 26, 2027 HRMY Watch '920 patent case interim notable
- Jan 28, 2027 INSM Watch ARIKAYCE FDA approval thesis-defining
- Jan 30, 2027 ABVX Watch Roche afimkibart AMETRINE-1 readout notable
- Jan 31, 2027 OLMA Watch Credit facility financing notable
- Feb 1, 2027 AGIO Watch Mitapivat sNDA SCD FDA approval thesis-defining
- ~Feb 2027 CADL Watch aglatimagene besadenovec FDA decision thesis-defining
- Feb 2027 ORIC Watch Mevrometostat MEVPRO-1 Pfizer topline thesis-defining
- Feb 2027 INMB Watch CORDStrom/Ebstrocel MAA filing major
- Feb 1, 2027 DBVT Watch Fareva Amboise factory FDA decision material
- Feb 2027 IRON Buy Dersimelagon LEO PDUFA date material
- Feb 2027 – Sep 2028 PTGX Hold ICOTYDE readout material
- Feb 2027 HRMY Watch '197/'947 patents AET litigation ruling notable
- Feb 2027 LQDA Spec buy YUTREPIA SSc-RP readout notable
- Feb 3 – May 3, 2027 PRLD Watch JAK2V617F program Incyte option partnership material
- Feb 12, 2027 BLTE Spec buy tinlarebant PDUFA date material
- Feb 27, 2027 CGEM Buy Zipalertinib EGFR FDA decision major
- Feb 27, 2027 ORIC Watch Zipalertinib Taiho-Cullinan PDUFA date material
- ~Mar 2027 COYA Avoid COYA 302 ALS corporate update notable
- Mar 2027 CRVS Buy Soquelitinib AD Ph3 interim notable
- Mar 2027 NRSN Avoid NDS Canada filing notable
- ~Mar 2027 STOK Watch Zorevunersen corporate update notable
- late 1Q 2027 TYRA Watch BEACH301 ACH readout notable
- Mar 3, 2027 EXEL Hold Zanzalintinib FDA approval material
- Mar 10, 2027 NTLA Spec buy lonvo-z HAE PDUFA date thesis-defining
- Mar 29, 2027 ETON Buy LIBERVANT PDUFA date thesis-defining
- Mar 31, 2027 MLYS Watch Lorundrostat Tranche B financing notable
Further out · through 4Q 2027
114
the rest of the next twelve months, held to the same bar: quarter-precision or finer, or a wider window an outside source has confirmed
- Early 2027 ABSI Buy ABS-201 AGA topline thesis-defining
- 1H 2027 ACHV Watch Cytisinicline smoking cessation FDA approval thesis-defining
- 2027 IONS Watch Obudanersen Ph3 topline thesis-defining
- 1H 2027 LBRX Watch NOVA-2 LB-102 schizophrenia topline thesis-defining
- 1H 2027 VOR Spec buy telitacicept Ph3 topline thesis-defining
- 1H 2027 ZNTL Spec buy Azenosertib topline thesis-defining
- 2027 EVMN Watch EVO756 topline major
- 1H 2027 IMTX Hold anzu-cel SUPRAME Ph3 interim major
- 2027 MAIA Spec buy THIO-104 Ph3 interim major
- 1H 2027 MAZE Watch MZE829 readout major
- 1H 2027 RARE Buy DTX301 OTC topline major
- 2027 RVMD Buy RASolve 301 daraxonrasib topline major
- 1H 2027 VOR Spec buy UPSTREAM MG Ph3 topline major
- 1H 2027 ZURA Watch Tibulizumab TibuSURE topline major
- 1H 2027 CTMX Spec buy CX-801 Ph1 readout material
- 1H 2027 CTMX Spec buy CX-801 readout material
- 2027 DBVT Watch Viaskin Peanut Toddlers 1-3yo BLA material
- 2027 DBVT Watch Toddler BLA ages 1-3 filing material
- 2027 JBIO Spec buy JADE201 Ph1 interim material
- 1H 2027 NVCT Spec buy NXP900 Ph1 readout material
- 1H 2027 PCVX Buy VAX-31 infant Ph2 topline material
- 1H 2027 PEPG Spec buy PGN-EDODM1 readout material
- 1H 2027 RXRX Watch REC-4881; REC-617; REC-3565 interim material
- 1H 2027 SANA Hold SG293 CAR-T readout material
- 1H 2027 SANA Hold SG293 readout material
- 1H 2027 TLX Watch TLX597-Tx PSMA topline material
- 1H 2027 ARVN Watch ARV-027 polyQ-AR readout notable
- 1H 2027 ENTX Watch EB612 IND filing notable
- 1H 2027 GLUE Buy MRT-8102 GFORCE-2 Ph2 start notable
- 2027 IDYA Watch IDE034 Ph1 interim notable
- 1H 2027 QTTB Watch Bempikibart Ph3 start notable
- 1H 2027 VNDA Watch Bysanti™ milsaperidone readout notable
- 1H 2027 XNCR Buy XmAb412 Ph1 interim notable
- early 2Q 2027 COYA Avoid COYA 302 ALS topline thesis-defining
- 2Q 2027 FDMT Watch 4D-150 4FRONT-1 AMD Ph3 topline thesis-defining
- 2Q 2027 IMCR Spec buy Tebentafusp TEBE-AM topline thesis-defining
- 2Q 2027 MGTX Watch AAV-hAQP1 pivotal topline thesis-defining
- 2Q 2027 BMEA Avoid Icovamenib COVALENT-212 topline major
- 2Q 2027 ADCT Spec buy ZYNLONTA + rituximab FL readout material
- Apr 1, 2027 HRMY Watch Pitolisant GR PDUFA date material
- 2Q 2027 INMB Watch CORDStrom/Ebstrocel BLA filing material
- 2Q 2027 QNRX Hold QRX003 topline material
- Apr 2027 RNTX Watch Tyvaso nebulized PDUFA date material
- Apr 2027 RNTX Watch TETON-1/-2 United Therapeutics PDUFA date material
- 2Q 2027 INMB Watch BLA filing notable
- ~Apr 1, 2027 TLSA Avoid Intranasal foralumab MSA readout notable
- Apr 14, 2027 INBX Spec buy Ozekibart PDUFA date major
- Apr 28, 2027 IMNM Spec buy Varegacestat FDA decision major
- Apr 30, 2027 LQDA Spec buy Settlement payments corporate update notable
- mid-2027 CRDL Avoid CardiolRx MAVERIC topline thesis-defining
- mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- by mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- mid-2027 IMMX Buy NXC-201 Ph2 topline thesis-defining
- mid-2027 INMB Watch CORDStrom/Ebstrocel EU decision thesis-defining
- May 1, 2027 QURE Watch AMT-130 ifezuntirgene inilparvovec PDUFA date thesis-defining
- mid-2027 VRCA Spec buy YCANTH (VP-102) common warts topline thesis-defining
- May 1, 2027 AXSM Avoid AXS-12 reboxetine PDUFA date major
- Mid-2027 CCCC Buy cemsidomide + elranatamab Ph1 readout major
- May 2027 CTNM Watch Admilparant (BMS) ALOFT-IPF full data major
- Mid-2027 IRON Buy Bitopertin FDA decision major
- mid-2027 VSTM Buy Avutometinib + defactinib RAMP Ph3 major
- mid-2027 VTVT Spec buy CATT1 Ph3 topline major
- mid-2027 CBIO Buy CR-001 + Kelun-Biotech ADCs combination material
- mid-2027 IMMX Buy NXC-201 BLA filing notable
- May 8, 2027 SEPN Watch BridgeBio encaleret PDUFA date material
- May 12, 2027 PTN Avoid Series J Warrants corporate update notable
- May 27, 2027 ZBIO Spec buy Obexelimab FDA approval material
- May 28, 2027 ETON Buy KHINDIVI FDA approval major
- Jun 2027 ELVN Watch ELVN-001 relcobatinib readout notable
- Jun 29, 2027 COGT Buy Bezuclastinib AdvSM PDUFA date thesis-defining
- Jun 29, 2027 IVVD Avoid PEMGARDA FDA decision major
- 2H 2027 ARDX Avoid Tenapanor ACCEL Ph3 topline thesis-defining
- 3Q 2027 CRVS Buy Soquelitinib Atopic Dermatitis Ph2 topline thesis-defining
- 2H 2027 LXEO Spec buy LX2006 FA pivotal topline thesis-defining
- 2H 2027 MPLT Spec buy ML-007C-MA VISTA Ph2 topline thesis-defining
- 2H 2027 NGNE Spec buy NGN-401 topline thesis-defining
- 2H 2027 OVID Spec buy OV329 topline thesis-defining
- 2H 2027 PALI Watch PALI-2108 UC topline thesis-defining
- 2H 2027 SABS Spec buy SAB-142 topline thesis-defining
- 2H 2027 SCYX Watch SCY-770 Ph2 topline thesis-defining
- 3Q 2027 STOK Watch Zorevunersen topline thesis-defining
- ~2H 2027 XNCR Buy XmAb942 UC topline thesis-defining
- 2H 2027 AXSM Avoid solriamfetol SUSTAIN Ph3 topline major
- 2H 2027 BCYC Watch Zelenectide pevedotin Ph2 readout major
- 2H 2027 BIOA Hold BGE-102 DME Ph1 topline major
- 2H 2027 CABA Buy myositis program DM pivotal topline major
- 2H 2027 FDMT Watch 4D-150 4FRONT-2 AMD Ph3 topline major
- 3Q 2027 GOSS Watch seralutinib PAH FDA approval major
- 2H 2027 HURA Avoid IFx-2.0 Ph3 topline major
- 2H 2027 IPSC Spec buy CNTY-813 topline major
- 3Q 2027 KPRX Watch KIO-301 topline major
- 2H 2027 SGMT Spec buy denifanstat AURORA Ph3 topline major
- ~Jul–Dec 2027 ABVX Watch Obefazimod PDUFA date material
- 3Q 2027 SYRE Hold SKYLINE Part B topline material
- Jul 2027 COYA Avoid RAPA-501 Ph2/3 readout notable
- Jul 2027 KZIA Watch Paxalisib TNBC enrollment done notable
- 3Q 2027 NRSN Avoid PrimeC Ph3 start notable
- 3Q 2027 NRSN Avoid PARAGON trial start notable
- 2H 2027 QTTB Watch Bempikibart readout notable
- 2H 2027 REPL Buy RP1 interim notable
- 2H 2027 STOK Watch Zorevunersen NDA filing notable
- 3Q 2027 SYRE Hold SPY120/SPY130/SPY230 combinations + all monotherapies notable
- 2H 2027 TARA Spec buy TARA-002 BLA filing notable
- ~Jul 2027 TLSA Avoid Intranasal foralumab ALS readout notable
- Jul 14, 2027 BCAX Watch '968 Patent PTAB Review FDA material
- ~Aug–Dec 2027 CADL Watch aglatimagene besadenovec PDUFA date thesis-defining
- Late-2027 KYMR Buy KT-621 BREADTH Ph2b topline thesis-defining
- Late 2027 (guided): REBOUND topline ANTX Watch Epetraborole REBOUND topline major
- end of 2027 TENX Watch TNX-103 enrollment done notable
- Sep 30, 2027 MLYS Watch Lorundrostat loan covenant corporate update notable
- 4Q 2027 ORIC Watch Mevrometostat MEVPRO-2 Pfizer topline major
- Oct 2027 MAZE Watch AZD2373 AstraZeneca Ph2b readout material
- 4Q 2027 MESO Watch Ryoncil adult SR-aGvHD interim material
- ~Oct 2027 PRLD Watch Menarini MEN2312 Ph1 readout notable
How to read this
Deeper blue means more of the thesis turns on the event — not a view on the stock and not a prediction of the outcome. A thesis-defining readout and a routine trial start are both just events until they report.
Dates reflect company guidance as reported in Biotech Distilled coverage and are frequently windows rather than fixed dates. Not investment advice.